{
    "guideline_id": "2024CSCO乳腺癌诊疗指南- .txt",
    "cancer_info": {
        "cancer_name": "Breast Cancer"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "HER2-positive early-stage breast cancer (neoadjuvant setting)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "TCbHP regimen (docetaxel + carboplatin + trastuzumab + pertuzumab)",
            "treatment_line": "Neoadjuvant",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HER2",
                    "status": "Positive",
                    "testing_guidance": "IHC 3+ or ISH positive"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on clinical trials"
        },
        {
            "clinical_context": "Triple-negative early-stage breast cancer (neoadjuvant setting)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Taxane + platinum-based chemotherapy + PD-1 inhibitor",
            "treatment_line": "Neoadjuvant",
            "biomarker_requirements": [
                {
                    "biomarker_name": "PD-L1",
                    "status": "CPS ≥1",
                    "testing_guidance": "CPS assessment on tumor and immune cells, using recurrence/metastasis tissue if available"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on TORCHLIGHT study"
        },
        {
            "clinical_context": "HER2-positive early-stage breast cancer (adjuvant setting, high risk)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Dual HER2-targeted therapy (trastuzumab + pertuzumab) ± neratinib",
            "treatment_line": "Adjuvant",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HER2",
                    "status": "Positive",
                    "testing_guidance": "IHC 3+ or ISH positive"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on APHINITY study"
        },
        {
            "clinical_context": "HER2-positive early-stage breast cancer (adjuvant setting, low risk)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "TCbH (docetaxel + carboplatin + trastuzumab) or wTH (weekly paclitaxel + trastuzumab)",
            "treatment_line": "Adjuvant",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HER2",
                    "status": "Positive",
                    "testing_guidance": "IHC 3+ or ISH positive"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on clinical trials"
        },
        {
            "clinical_context": "Triple-negative early-stage breast cancer (adjuvant setting)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Platinum-based chemotherapy (e.g., TP regimen) followed by capecitabine maintenance or olaparib (for BRCA mutation)",
            "treatment_line": "Adjuvant",
            "biomarker_requirements": [
                {
                    "biomarker_name": "BRCA1/2",
                    "status": "Mutated",
                    "testing_guidance": "Germline testing for triple-negative patients, young patients, or those with family history"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on OlympiA study"
        },
        {
            "clinical_context": "HR-positive/HER2-negative early-stage breast cancer (adjuvant setting, high risk)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "For premenopausal: OFS (ovarian function suppression) + AI/TAM ± CDK4/6 inhibitor; for postmenopausal: AI for 5 years ± CDK4/6 inhibitor (e.g., abemaciclib or ribociclib for 2 years)",
            "treatment_line": "Adjuvant",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HR",
                    "status": "Positive",
                    "testing_guidance": "ER and PR testing required"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on MonarchE and NATALEE studies"
        },
        {
            "clinical_context": "HER2-positive advanced/metastatic breast cancer (first-line)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "THP (taxane + trastuzumab + pertuzumab) or TH + pyrotinib",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HER2",
                    "status": "Positive",
                    "testing_guidance": "IHC 3+ or ISH positive"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on CLEOPATRA and PHOEBE studies"
        },
        {
            "clinical_context": "HER2-positive advanced/metastatic breast cancer (second-line)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "T-DXd or T-DM1",
            "treatment_line": "Second-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HER2",
                    "status": "Positive",
                    "testing_guidance": "IHC 3+ or ISH positive"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on DESTINY-Breast03 study"
        },
        {
            "clinical_context": "HR-positive/HER2-negative advanced/metastatic breast cancer (first-line)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Fulvestrant + CDK4/6 inhibitor (e.g., abemaciclib, dalpiciclib, palbociclib)",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HR",
                    "status": "Positive",
                    "testing_guidance": "ER and PR testing required"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on clinical trials"
        },
        {
            "clinical_context": "HR-positive/HER2-negative advanced/metastatic breast cancer (after CDK4/6 inhibitor failure)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "PI3K inhibitor (alpelisib + fulvestrant for PIK3CA mutation) or AKT inhibitor (capivasertib + fulvestrant) or HDAC inhibitor (cidaostat + exemestane)",
            "treatment_line": "Second-line or later",
            "biomarker_requirements": [
                {
                    "biomarker_name": "PIK3CA",
                    "status": "Mutated",
                    "testing_guidance": "Testing for PIK3CA mutation required"
                }
            ],
            "recommendation_level": "Level II Recommendation",
            "evidence_level": "Based on SOLAR-1 and ACE studies"
        },
        {
            "clinical_context": "Triple-negative advanced/metastatic breast cancer (first-line)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Taxane/platinum-based chemotherapy ± PD-1 inhibitor (for PD-L1 CPS ≥1)",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "PD-L1",
                    "status": "CPS ≥1",
                    "testing_guidance": "CPS assessment on recurrence/metastasis tissue"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on KEYNOTE-355 study"
        },
        {
            "clinical_context": "Triple-negative advanced/metastatic breast cancer (later-line)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Sacituzumab govitecan or datopotamab deruxtecan",
            "treatment_line": "Second-line or later",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on TROPiCS-02 and BEGONIA studies"
        },
        {
            "clinical_context": "Bone metastasis",
            "recommendation_type": "Management Plan",
            "recommendation_content": "Bone-modifying agents (zoledronic acid or denosumab) with surgery/radiotherapy for high-risk pathological fractures (Mirels score ≥8)",
            "treatment_line": "Supportive care",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on clinical guidelines"
        },
        {
            "clinical_context": "Brain metastasis",
            "recommendation_type": "Management Plan",
            "recommendation_content": "Local therapy (surgery or stereotactic radiosurgery) ± systemic therapy (e.g., T-DXd or pyrotinib for blood-brain barrier penetration)",
            "treatment_line": "Supportive care",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HER2",
                    "status": "Positive",
                    "testing_guidance": "Required for targeted therapy eligibility"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Based on PERMEATE study"
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "HER2 overexpression predicts efficacy of HER2-targeted therapies; HER2-low expression indicates eligibility for T-DXd; HR positivity predicts sensitivity to endocrine therapy; BRCA1/2 mutation indicates DNA repair defect and eligibility for PARP inhibitors; PIK3CA mutation indicates PI3K pathway activation and eligibility for alpelisib; PD-L1 positivity (CPS ≥1) in triple-negative breast cancer predicts benefit from immunotherapy."
    },
    "tcm_recommendations": [
        {
            "syndrome_type": "Not specified",
            "tcm_treatment_plan": "Traditional Chinese medicine to alleviate bone pain in bone metastasis",
            "recommendation_grade": ""
        },
        {
            "syndrome_type": "Not specified",
            "tcm_treatment_plan": "Traditional Chinese medicine to support white blood cell count for bone marrow suppression from CDK4/6 inhibitors",
            "recommendation_grade": ""
        },
        {
            "syndrome_type": "Spleen deficiency with dampness",
            "tcm_treatment_plan": "Traditional Chinese medicine for spleen strengthening and dampness resolving to manage diarrhea from pyrotinib",
            "recommendation_grade": ""
        }
    ]
}